Niraparib Exhibits a Synergistic Anti-Tumor Effect with PD-L1 Blockade by Inducing an Immune Response in Ovarian Cancer

Programmed death ligand 1 (PD-L1) expression in human ovarian cancer cells after PARP inhibitors treatment was examined by western blotting and flow cytometry.